Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Post by LithLoveron Jul 05, 2023 4:59pm
167 Views
Post# 35528069

Warrant reprice in effect for the next 3 trading days

Warrant reprice in effect for the next 3 trading days8,730,647 outstanding common share purchase warrants. The new exercise price of the warrants will be CDN$0.065 and the temporary repricing will take effect on July 5 and close on July 10, 2023. We believe this represents a great opportunity to those shareholders who have supported us over the last few years to participate further in the growth of StageZero and represents CDN $567,492 in possible capital to StageZero should all of the warrants be exercised. This capital would be directly deployed into growth focused activities such as the METRICS II study and support of our growing list of partnerships.
-------------

Hard to buy any significant shares in the market at 0.065 or higher as it would drive the price up and only 100,000 or so was available.  We will see what happens and if there is any interest in the 8.7 million warrants.  

Current level 2 ask:


0.070 132,000
 
132,000 shares
0.075 25,000
 
25,000 shares
0.080 82,000
 
82,000 shares
0.085 73,000
 
73,000 shares
0.090 12,000

<< Previous
Bullboard Posts
Next >>